LTC Webinar: The relationship between the VC and its portfolio companies

‘The reason we are so excited about Biotech investments is that the exits we have are oversized in terms of returns. But also with that - we are making an impact on the way we live our lives.’

 

We were pleased to host a webinar with ARTIS Ventures, pioneering investors in techbio: at the intersection of life sciences and computer sciences. The discussion focused on the relationship between the VC and its portfolio companies. It was great to see first-hand the close relationships between Artis and the CEOs/ Founders within their portfolio.

 

A special thank you to our fantastic speakers:

• Vas Bailey, PhD, partner at ARTIS Ventures  which invests in breakthrough healthcare companies.

• Connor Landgraf, co-founder and CEO of Eko, on a mission to improve monitoring for cardiovascular and pulmonary disease patients.

• Pavle Jeremić, CEO and founder of Aether Biomachines, a company operating at the intersection of manufacturing, synthetic biology, and deep learning.

• Daniel Dornbusch, CEO at Excision BioTherapeutics, developing advanced gene editing therapeutics  to treat life-threatening diseases caused by viral infections.

 

It is always encouraging to hear about breakthroughs and success stories in BioTech and healthcare! The future feels more positive as a result of some of the great work discussed.

​

​

Please also subscribe to our newsletter to receive information about our future activities.